Core Viewpoint - Disc Medicine, Inc. is hosting a virtual KOL investor event to discuss anemia of myelofibrosis (MF) and the treatment landscape, including clinical data and development plans for its investigational drug DISC-0974 [1][2] Group 1: Event Details - The virtual event is scheduled for May 9, 2025, at 1:00 PM ET / 10:00 AM PT [1] - Presentations will include insights from leading experts on myeloproliferative neoplasms (MPNs) and the unmet need for anemia-focused treatments [2] - A live webcast will be available on Disc's Investor Relations page, with a replay accessible for 90 days [3] Group 2: DISC-0974 Overview - DISC-0974 is a monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin production and increase serum iron levels in patients with anemia of inflammation [4] - The drug was in-licensed from AbbVie in 2019 and has shown clinical proof-of-mechanism in previous trials [4] - Ongoing clinical trials include a Phase 2 trial in MF anemia and a Phase 1b/2a trial in chronic kidney disease patients [4] Group 3: Anemia of Myelofibrosis - Myelofibrosis affects an estimated 25,000 patients in the U.S., with over 80% presenting with anemia at diagnosis [6] - Hepcidin levels are approximately 12-fold elevated in MF patients, correlating with disease severity and the need for red blood cell transfusions [6] Group 4: Company Background - Disc Medicine is focused on developing novel treatments for serious hematologic diseases, targeting biological pathways related to red blood cell biology [7][8]

Core Insights - AbbVie has received FDA approval for RINVOQ (upadacitinib) as the first oral JAK inhibitor for treating giant cell arteritis (GCA) in adults, marking its ninth approved indication in the U.S. [1][2] - The approval is based on the successful results of the Phase 3 SELECT-GCA clinical trial, which demonstrated that 46.4% of patients on RINVOQ achieved sustained remission compared to 29.0% on placebo [2][6] - GCA is a significant autoimmune disease that can lead to severe complications, and the new treatment option aims to reduce reliance on glucocorticoids, which have substantial side effects [2][7] Company Overview - AbbVie is committed to addressing unmet needs in immune-mediated diseases, as highlighted by the introduction of RINVOQ for GCA [2][31] - The company has a strong focus on rheumatology, having developed multiple therapies for various autoimmune conditions [31][32] Clinical Trial Insights - The SELECT-GCA trial involved 428 patients and assessed the efficacy and safety of RINVOQ in combination with a corticosteroid taper regimen [6][2] - The trial's results support the potential for RINVOQ to provide sustained remission in GCA patients, which is a significant advancement in treatment options [2][6] Market Implications - The approval of RINVOQ for GCA expands AbbVie's portfolio in the rheumatology space, potentially increasing market share and revenue from this therapeutic area [1][2] - The introduction of RINVOQ may shift treatment paradigms for GCA, offering a new alternative to traditional glucocorticoid therapies [2][7]

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were impacted by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - AbbVie's stock price has seen a positive momentum following its first-quarter earnings report, outperforming the S&P 500 index due to bullish analyst notes [1]. Group 1: Analyst Recommendations - BMO Capital's analyst Evan David Seigerman maintained an "outperform" recommendation for AbbVie with a price target of $215 per share [2]. - HSBC highlighted AbbVie as a good value investment amidst downgrades of other healthcare stocks, indicating a positive outlook for the company [5]. Group 2: Earnings Performance - AbbVie's first-quarter earnings report showed strong performance, particularly from high-revenue products Skyrizi and Rinvoq, which compensated for expected declines in Humira sales [3]. - The company raised its per-share earnings guidance, which was viewed positively by analysts [4]. Group 3: Market Context - AbbVie's stock gained over 3% during the trading session, contrasting with the S&P 500's less than 0.1% gain, indicating strong investor confidence [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have impacted the stock price prior to a merger announcement with AbbVie Inc. [1][4] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [3]. - Shareholders are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for June 3, 2025 [5]. Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023 secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [4]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [4]. Group 3: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case [5]. - Participation in the class action has no cost or obligation for shareholders [5].

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative solutions [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs and fluids [3] - Halozyme has impacted over one million patients through its technology, which is used in ten commercialized products across more than 100 global markets [3] Product Development - Halozyme develops, manufactures, and commercializes drug-device combination products, leveraging advanced auto-injector technologies to enhance convenience, reliability, and patient comfort [4] - The company has two proprietary commercial products: Hylenex® and XYOSTED®, along with partnered products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Financial Results - Halozyme will release its first quarter 2025 financial and operating results on May 6, 2025, after the market closes [1] - A conference call to discuss these results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, with live access available through pre-registration [1][2]

CONTACT US HERE: NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ABBV during the timef ...

Core Viewpoint - AbbVie's Q1 results showed strong revenue growth of 8.4% year over year, driven by autoimmune disease drugs Skyrizi and Rinvoq, and the company raised its full-year earnings guidance, but potential tariff issues and international reference pricing pose significant risks to its future performance [1][4][5]. Group 1: Financial Performance - AbbVie's revenue increased by 8.4% year over year, primarily due to the success of Skyrizi and Rinvoq [1]. - The company exceeded Wall Street's expectations for both revenue and earnings in Q1 [1]. - AbbVie raised its full-year earnings guidance, although it included a disclaimer regarding potential trade policy changes [4]. Group 2: Tariff Concerns - Current tariffs have not impacted AbbVie, as pharmaceuticals were exempt from the Trump administration's tariffs [2]. - President Trump announced plans for a major tariff on pharmaceuticals, aiming to encourage domestic manufacturing [3]. - CEO Robert Michael indicated that any tariff impacts would likely align with those faced by peers, and AbbVie would not pass on price increases to customers but may seek cost efficiencies [4][9]. Group 3: International Reference Pricing - The Trump administration is considering implementing international reference pricing, which could significantly affect U.S. drug prices and pose an "existential threat" to the industry [5][6]. - Michael expressed concerns about the potential negative impact of international reference pricing on U.S. healthcare and innovation during the Q1 earnings call [7]. - Previous attempts to implement such pricing were halted by federal courts, and any new efforts may face strong lobbying from the pharmaceutical industry [10].

Group 1 - AbbVie released financial results for Q1 2025, beating Wall Street expectations [1] - The company is under the leadership of Rob Michael, who has over two decades of investment experience [1] Group 2 - Allka Research focuses on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [1] - The firm aims to deliver substantial returns and strategic insights to clients, simplifying investment strategies for accessibility [1] - Allka Research contributes analyses and perspectives to the Seeking Alpha community, fostering informed investing [1]

Core Viewpoint - The current economic environment presents a favorable opportunity for investors to consider solid dividend stocks, which tend to be more resilient than non-dividend-paying companies amid market volatility and potential recession [1]. Group 1: Dividend Stocks Overview - Four recommended dividend-paying stocks during the current market sell-off are AbbVie, Amgen, Bristol Myers Squibb, and Zoetis [2]. Group 2: AbbVie - AbbVie is recognized for its strong position in immunology, despite facing challenges such as a patent cliff and clinical setbacks [3]. - The company has increased its 2027 revenue guidance for key products Skyrizi and Rinvoq by $4 billion to over $31 billion, indicating strong growth potential [4]. - AbbVie has a robust pipeline and a history of increasing dividends for 53 consecutive years, with a forward yield of 3.9%, significantly above the S&P 500 average of 1.3% [5]. Group 3: Amgen - Amgen's shares faced a decline due to underperformance of its weight loss candidate, MariTide, but the company has a strong portfolio with over 10 blockbuster drugs [6]. - Key growth drivers include asthma medicine Tezspire and FDA-approved Tepezza for thyroid eye disease, supporting a strong revenue outlook [7]. - Since initiating dividends in 2011, Amgen has increased payouts by 750%, with a forward yield exceeding 3.5% [8]. Group 4: Bristol Myers Squibb - Bristol Myers is facing significant patent cliffs, particularly for its best-sellers Opdivo and Eliquis, but has managed to secure new approvals to mitigate revenue loss [9]. - Newer medicines like Reblozyl and Opdualag are expected to drive future sales growth [10]. - The company has increased its dividend by nearly 68% over the past decade, offering a yield of 5.1% [11]. Group 5: Zoetis - Zoetis, a leader in animal health, started the year with disappointing guidance but has a strong portfolio with 15 products generating over $100 million in annual sales [12]. - The company is expected to overcome current challenges with its key product Apoquel and has new approvals in the pipeline to drive growth [13]. - Zoetis has increased its dividends by about 500% over the past decade, although its yield is 1.4% [14].